PT - JOURNAL ARTICLE AU - Thomas Salmon AU - Mitchell Titley AU - Zaid Noori AU - Mark Crosby AU - Rajiv Sankaranarayanan TI - Anticoagulants and Antiplatelets in COVID-19: Impact on Survival and Thromboembolism Development AID - 10.1101/2021.07.03.21254541 DP - 2021 Jan 01 TA - medRxiv PG - 2021.07.03.21254541 4099 - http://medrxiv.org/content/early/2021/07/07/2021.07.03.21254541.short 4100 - http://medrxiv.org/content/early/2021/07/07/2021.07.03.21254541.full AB - Background Higher rates of venous and arterial thromboembolism have been noted in coronavirus disease-2019 (COVID-19). There has been limited research on the impact of anticoagulant and antiplatelet choice in COVID-19.Methods This was a single-centre retrospective cohort study of 933 patients with COVID-19 infection presenting between 01/02/2020 and 31/05/2020. Survival time at 90 days post-diagnosis and thromboembolism development were the measured outcomes.Results Of 933 total patients, mean age was 68 years and 54.4% were male. 297 (31.8%) did not survive at 90 days. A Cox proportional hazards model analysis found no statistically significant relationship between anticoagulant or antiplatelet choice and survival (p<0.05).57 (6.3%) developed thromboembolism. Antiplatelet choice was not shown to have a statistically significant relationship with thromboembolism development. Warfarin and direct oral anticoagulant (DOAC) use did not have a statistically significant impact on thromboembolism development (p<0.05). Therapeutic low-molecular-weight heparin (LMWH) use was associated with increased thromboembolism risk (Odds ratio = 14.327, 95% CI 1.904 – 107.811, p = 0.010).Conclusions Antiplatelet choice was shown to have no impact on survival or thromboembolism development in COVID-19. Anticoagulant choice did not impact survival or thromboembolism development, aside from LMWH. Therapeutic LMWH use was associated with increased risk of thromboembolism. However, it should be noted that the sample size for patients using therapeutic LMWH was small (n=4), and there may be confounding variables affecting both LMWH use and thromboembolism development. These findings should be repeated with a larger sample of patients using therapeutic LMWH with additional adjustment for cofounding variables.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approved by Aintree University Hospital audit and research department ethics reviewAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAvailable on request from author.COVID-19Coronavirus disease 2019WHOWorld Health OrganisationDOACDirect Oral AnticoagulantLMWHLow Molecular Weight HeparinPCRPolymerase Chain ReactionBSTIBritish Society of Thoracic ImagingA.FibAtrial FibrillationCIConfidence IntervalSDStandard Deviation